Pharmacist Enhanced Service for Cardiovascular Risk Reduction
- Conditions
- Cardiovascular Risk Factor
- Interventions
- Other: Enhanced pharmacist serviceOther: Usual care
- Registration Number
- NCT04220788
- Lead Sponsor
- Monash University
- Brief Summary
Pharmacist services such as medication review, counselling and treatment adherence clinics can improve clinical, health related quality of life and economic outcomes. To prove this hypothesis a step-wedge, cluster randomized controlled trial will be held in primary care centers of the public health system of Malaysia. Participants who have a high risk of cardiovascular risk factors currently seeking care in primary care will be recruited. Control group will receive usual care and the intervention arm will be seen by a pharmacist prior to their follow-up, with a comprehensive medication review, counselling and dietary advice consultations every month for three months. Participating pharmacist will be trained in cardiovascular prevention pharmacotherapy, interview skills, educational techniques, and develop personalized plan for every participant. The investigators plan to randomize up to 2100 participants who are currently receiving care in the primary care clinics in the district of Petaling by modifying the current workflow in primary care, whereby the investigators aim to get participants who are at high risk to undergo counselling as well as a medication review with proper pharmaceutical care delivered to them prior to seeking their medical doctor to receive care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Patients with diabetes
- Patients with chronic kidney disease (eGFR <60ml/min/1.73m2)
- Patients with established atherosclerotic vascular disease (via patient health records or selfreport) including cerebrovascular disease (prior stroke or transient ischemic attack), cardiovascular disease (myocardial infarction, acute coronary syndrome, stable angina, or revascularization), or peripheral arterial disease (symptomatic and/or ankle brachial index <0.9)
- Primary prevention patients with multiple risk factors and Framingham risk score >30%
- Unwilling to participate/sign consent form
- Unwilling or unable to participate in regular follow-up visits
- Pregnancy
- Undergoing existing medication therapy adherence clinic conducted by the Pharmacy Unit
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Enhanced pharmacist service Enhanced pharmacist service The advanced care group will be undergo a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA) with the pharmacist Usual care Usual care Patients in the usual care arm will receive their usual care which they will obtain care from their doctor,nurse and pharmacist where appropriate
- Primary Outcome Measures
Name Time Method Change in cardiovascular risk scores 3 months The difference from baseline to 3 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
- Secondary Outcome Measures
Name Time Method Change in cardiovascular risk scores 24 months The difference from baseline to 24 months in the estimated cardiovascular risk between advanced care and usual care groups assessed using the Framingham scale
Achievement of recommended cholesterol, blood pressure and glycemic control targets 3 months Number of individual achieving target cholesterol, blood pressure and glycemic control target
Proportion of patients receiving appropriate medication 3 months Number of patients receiving appropriate BP, cholesterol and diabetes medication
Trial Locations
- Locations (1)
Shaun Lee
🇲🇾Subang Jaya, Selangor, Malaysia